LumiThera Introduces the Valeda Light Delivery System

Valeda is the first approved treatment for dry age-related macular degeneration (AMD) using photobiomodulation (PBM). Valeda uses a multi-wavelength approach to stimulate critical targets of cellular function, leading to improved energy production within the mitochondria.

AMD is the leading cause of blindness in adults over 65. Approximately 90% of patients with AMD have the dry form, and 10% have the wet form.

LumiThera is at the forefront of the development of  PBM treatments for patients with AMD and other degenerative ocular diseases.

Indications for Use:  The indicated use is for treatment of ocular damage and disease using photobiomodulation, including inhibition of inflammatory mediators, edema or drusen deposition, improvement of wound healing following ocular trauma or surgery, and increase in visual acuity and contrast sensitivity in patients with degenerative diseases such as dry age-related macular degeneration.